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Abstract
Introduction: Despite large experience in the management of severe burn injury, there are still controversies 
regarding the best type of fluid resuscitation, especially during the first 24 hours after the trauma. Therefore, our study 
addressed the question whether hyperoncotic hydroxyethyl starch (HES) 200/0.5 (10%) administered in combination 
with crystalloids within the first 24 hours after injury is as effective as 'crystalloids only' in severe burn injury patients.
Methods: 30 consecutive patients were enrolled to this prospective interventional open label study and assigned 
either to a traditional 'crystalloids only' or to a 'HES 200/0.5 (10%)' volume resuscitation protocol. Total amount of fluid 
administration, complications such as pulmonary failure, abdominal compartment syndrome, sepsis, renal failure and 
overall mortality were assessed. Cox proportional hazard regression analysis was performed for binary outcomes and 
adjustment for potential confounders was done in the multivariate regression models. For continuous outcome 
parameters multiple linear regression analysis was used.
Results: Group differences between patients receiving crystalloids only or HES 200/0.5 (10%) were not statistically 
significant. However, a large effect towards increased overall mortality (adjusted hazard ratio 7.12; P = 0.16) in the HES 
200/0.5 (10%) group as compared to the crystalloids only group (43.8% versus 14.3%) was present. Similarly, the 
incidence of renal failure was 25.0% in the HES 200/0.5 (10%) group versus 7.1% in the crystalloid only group (adjusted 
hazard ratio 6.16; P = 0.42).
Conclusions: This small study indicates that the application of hyperoncotic HES 200/0.5 (10%) within the first 24 hours 
after severe burn injury may be associated with fatal outcome and should therefore be used with caution.
Trial registration: NCT01120730.
Introduction
In the VISEP (efficacy of volume substitution and insulin
therapy in severe sepsis) study the application of hydroxy-
ethyl starch (HES) 200/0.5 (10%) showed an increased
incidence of renal failure in ICU patients, which was
clearly dose-dependent. In fact the manufacturer's rec-
ommended dose of 20 ml/kg was exceeded in almost 60%
of cases. The authors concluded that fluid resuscitation
with HES 200/0.5 (10%) is harmful to patients with severe
sepsis, because it leads to renal impairment and, at high
doses, affects long-term survival. HES solutions should
therefore be avoided in severe sepsis [1]. After publica-
tion of the VISEP trial there is an ongoing debate about
fluid resuscitation, the role of crystalloids and colloids in
the critically ill patient, the safety of HES, and even about
the design of the VISEP study [2,3]. In this context and for
ethical reasons (avoiding further harm to severe burn vic-
tims) we analyzed the results of this open-label interven-
tional study, performed some years ago at our institution,
to contribute to this important discussion.
Despite much experience in the management of severe
burn trauma patients, controversies regarding the best
type of fluid resuscitation, especially within the first 24
hours after trauma, are still going on.
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pathophysiological changes take place. Systemic inflam-
mation leads by release of different mediators such as leu-
kotrienes, prostaglandins and particularly histamine, in
combination with complement activation products to a
massive capillary leak [4,5]. Intravascular molecules leak
into the extravascular space, causing hypovolemia and
shock [6]. Changes in capillary membrane permeability
also produce electrolytic alteration with intracellular
sodium accumulation with consecutive cellular swelling
[7]. Tissue edema normally occurs within a few hours.
Leakage of plasma proteins into the extravascular space
contributes in a large extent to edema formation. The
capillary leak is believed to stop between 8 and 24 hours
after trauma, but data varys [4,8].
There is strong evidence that starting fluid resuscita-
tion early improves clinical outcome in patient with
severe burn injury [9], but there is no consensus about
which kind of fluids would be the optimal treatment. In
order to increase plasma osmolarity and thus reduce fluid
losses into the extravascular space, some authors propose
to add hypertonic solutions (e.g. hypertonic saline) in
fluid resuscitation in these patients [10,11]. Fluid resusci-
tation in particular with excessive amounts of crystalloids
in severe burn victims may lead to edema formation and
thus contribute to respiratory failure, acute respiratory
distress syndrome (ARDS) and/or abdominal compart-
ment syndrome (ACS) [12]. ACS has a high impact on
mortality in such patients and in one study 22 out of 25
patients died [13]. One of the treatment options for
patients with ACS might be surgical abdominal decom-
pression [14]. The main controversy about fluid resusci-
tation in severe burns is about the use or the avoidance of
colloids, which solution to use and, last but not least,
when to begin with the administration of colloids [15].
Among the available colloids, albumin and fresh frozen
plasma (FFP) are mainly used. The Cochrane Injuries
Group presented a relative risk of death after albumin
administration of 2.4 in a metaanalysis [16]. Nevertheless,
the infusion of albumin is very common in fluid manage-
ment of severe burns [17,18].
The aim to reduce pulmonary complications (i.e.
ARDS) and ACS by volume overload raised the issue of
the application of colloids such as hyperoncotic HES.
Colloids given after 24 hours in addition to crystalloids
the extravascular lung water index did not increase [19].
The major concern about hyperoncotic HES 200/0.5
(10%) administration consists of its negative effects on
renal function leading to renal failure and renal replace-
ment therapy (RRT) [1]. Hyperoncotic HES used as a
plasma-volume expander in brain-dead kidney donors
has been shown to induce osmotic-nephrosis-like lesions
and immediately impaired renal function in kidney-
transplant recipients [20].
There is no evidence of whether the application of
hyperoncotic HES 200/0.5 (10%) within the first 24 hours
would improve or deteriorate the outcome in patients
with severe burn injuries. Expert opinions of burn spe-
cialists consist of strictly avoiding colloids such as HES
during the first 24 hours [21]. This restriction is based on
reports from the early 1970 s expressing the fear of over-
loading the interstitial compartment with colloids due to
increased capillary leakage in the early stage of trauma,
which later might have negative effects on wound healing
after surgical treatment [22,23].
Therefore, in our study we also addressed the question
of whether the administration of hyperoncotic HES 200/
0.5 (10%) within the first 24 hours in combination with
crystalloids is as effective as crystalloids only in reducing
the total amount of infused fluids and therefore might
reduce complications such as pulmonary failure or
abdominal compartment syndrome. Furthermore, we
addressed overall mortality, the incidence of renal failure
and whether surgical treatment could be started within
the first three days after trauma.
Materials and methods
The local ethical committee re-approved the analysis and
protocol of the study in 2007 and waived the need for addi-
tional written informed consent for this data analysis 10
years after the study. Data were collected and analyzed
from 30 consecutive patients with severe burns (> 20%
body surface area) who were admitted to the burn unit of
the University Hospital of Zurich, Switzerland, from
August 1997 to July 1999. Patients were assigned in a pro-
spective interventional open label study design either to a
traditional crystalloids only ('Baxter group') resuscitation
protocol (Baxter formula 4 ml crystalloids/kg/% deep
burned body surface area) in the first 24 hours or to a new
approach 'HES 200/0.5 (10%) group' with colloids and crys-
talloids (2 ml crystalloids/kg/% deep burned body surface
area plus 0.5 ml HES 200/0.5 (10%)/kg/% deep burned
body surface area). The crystalloid given was lactated
Ringer's solution (LR). Topical treatment of burn wounds
was standardized in all patients using silver sulfadiazine.
The patient characteristics are shown in Table 1.
Groups were not well balanced for age. Therefore, we
used multivariable regression models (Cox proportional
hazard regression for time to event data and linear
regression for continuous outcomes) with outcomes as
the independent variable and group as the dependent
variable while adjusting for potential confounders (age,
gender percent burn, acute physiology and chronic health
evaluation (APACHE) II, baseline creatinine).
Béchir et al. Critical Care 2010, 14:R123
http://ccforum.com/content/14/3/R123
Page 3 of 9Study protocol
After admission to our hospital patients were assigned
either to the traditional crystalloids only (Baxter group)
or to the experimental resuscitation regimen (HES 200/
0.5 (10%) group). The estimated amounts of fluids were
calculated according to the above mentioned formulas.
Except for the different fluid management, all patients
were treated and monitored in the same manner accord-
ing to the same target variables (urinary output ≥1.0 ml/
kg/hour, mean arterial pressure ≥65 mmHg, hematocrit
35% to 45%, and serum lactate ≤2.0 mmol/l). If target val-
ues could not be reached with volume therapy alone, nor-
epinephrine infusion was added. Blood glucose levels
were kept between 6 to 12 mmol/l. Besides the ICU stan-
dard monitoring we assessed the administered amount of
fluids, creatinine clearance (Cockroft formula) every 24
hours for the first three days, urinary output, the Horo-
vitz-Index after 72 hours, ventilator days and the inci-
dence of ARDS. We analysed hematocrit, white blood
cells (WBC), C-reactive protein (CRP), glutamat-oxalace-
tat-transaminase and glutamat-pyruvat-transaminase
(GPT) at days one, two, three and seven. Furthermore, we
assessed ICU and hospital days, the incidence of sepsis,
overall mortality, and the beginning of surgical proce-
dures within the first three days after trauma.
Statistical analysis
Binary data are presented as proportions and continuous
variables as mean ± standard deviation. For binary out-
comes we used a Cox proportional hazard regression
with the event (e.g. mortality) as dependent variable and
fluid resuscitation therapy (HES or Baxter) as indepen-
dent variable. As this was not a randomized trial we
adjusted for potential confounders (age, gender, percent
burn, APACHE II and baseline creatinine) in the multi-
variate regression models. For continuous outcomes (e.g.
creatinine clearance) we used a multiple linear regression
analysis with the same independent variables as
described above. For comparison of the blood markers we
used the method of analysis of variance for repeated mea-
surements (adjusted for potential confounders age, gen-
der, percent burn, APACHE II and baseline creatinine).
We conducted all analyses using SPSS for Windows (ver-
sion 12.0.1, SPSS Inc, Chicago, Illinois, USA).
Results
Thirty patients were included in the study, 14 to the crys-
talloids only group and 16 to the HES 200/0.5 (10%)
group. The patient characteristics including degree of
burn are shown in Table 1.
Was there a difference in the total amount of fluids?
The estimated amount of fluids for the first 24 hours was
11,150 (± 4115) ml LR in the crystalloids only group ver-
sus 7,082 (± 5142) ml LR and 1,409 (± 642) ml HES in the
HES 200/0.5 (10%) group. The effectively given amounts
of fluids in the two groups over the days one to three are
shown in Table 2. Approximately 1.5-fold of the initially
Table 1: Participant characteristics
Baxter group
(n = 14)
HES group
(n = 16)
P value
Age (years) 35.9 ± 14.2* 49.4 ± 22.0 0.06
Number of male participients (%) 11 (78.6) 13 (81.3) 0.86
Weight (Kg) 75.3 ± 11.3 72.7 ± 15.2 0.60
APACHE II score (points) 8.4 ± 5.8 9.1 ± 2.2 0.65
Creatinine baseline (μmol/l) 74.6 ± 9.8 82.7 ± 19.7 0.18
2nd + 3rd degree burn (%) 37.4 ± 14.2 40.0 ± 13.8 0.62
Burn type (number of patients) 0.17
- fire 12 11
- fire/explosion 1 1
- steam/scalding liquids 0 4
- electrical/chemical 0 0
- flash injury 1 0
Number of patients with inhalation injury (%) 2 (14.2) 3 (21.4) 0.51
Time from burn to iv-start (minutes) 100 ± 153 59 ± 38 0.44
Time from burn to hospital admission (minutes) 175 ± 173 141 ± 81 0.90
Time to first surgery (days) 5 ± 4 4 ± 3 0.87
* Values are means ± standard deviation unless stated differently. APACHE, acute physiology and chronic health evaluation; HES, 
hydroxyethyl starch.
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groups. There was a protocol violation as four patients in
the crystalloids only group were treated with 1325 (± 538)
ml HES during the operating procedures at days two and
three and one patient of the HES 200/0.5 (10%) group
received 200 ml of albumin during operating procedures.
Overall, the addition of colloids and crystalloids reveals
that there was no difference in the total amount of fluids
given between the groups.
Was there an influence on mortality or renal failure?
No statistically significant differences were found
between the HES 200/0.5 (10%) and crystalloids only
groups. However, a large effect towards increased mortal-
ity (hazard ratio 7.12) and renal failure leading to contin-
uous RRT (CRRT; hazard ratio 6.16) was detected for
HES (Table 3 and Figure 1). Looking at single patients
developing renal failure, CRRT was started on days 8 to
19 postinjury. Renal parameters such as hourly urinary
output after 72 hours and daily creatinine clearance
(cockroft formula) were not significantly different.
In conclusion, the application of HES 200/0.5 (10%)
may have a negative impact on mortality and may pro-
mote renal failure.
Was there a reduction of complications?
There were no differences between the groups in the inci-
dence of ARDS, ventilator days and the Horovitz quotient
after 72 hours. ACS occurred in none of the patients. The
incidence of sepsis was the same in both groups. The
adjusted length of hospital and ICU stay was not different
between the groups (Table 3).
Taken together, there was no difference in complica-
tions between the groups.
Was the surgical procedure disturbed with the application 
of HES?
Surgical treatment of the groups did not differ; neither
the timepoint of the first surgical intervention (day three
surgery) nor completion of surgical coverage of the
burned body surface areas was delayed (Table 3).
The application of colloidal HES did not influence tim-
ing of surgical procedures.
Was there a difference in blood markers between the 
groups?
Hematocrit, WBC, CRP and GPT did not differ between
groups during the first seven days of the study (Figure 2).
We could not discriminate any different pattern of
inflammation or hematocrit between the two groups.
Discussion
Similarly to the VISEP trial in septic patients our study
also showed that the application of HES 200/0.5 (10%) in
a population of severely burned patients may be associ-
ated with fatal outcome in comparison to traditional fluid
resuscitation with crystalloids only.
Table 2: The intervention protocol
Baxter group
(n = 14)
HES group
(n = 16)
Fluid volumes calculated for first 24 hours
Lactated Ringer's Solution (ml) 11,150 ± 4,115* 7,082 ± 5,142
HES (ml) 0 1,409 ± 642
Fluid volumes given
Lactated Ringer's Solution (ml)
After 24 hours 18,667 ± 9,438 12,692 ± 4,785
After 48 hours 22,220 ± 11,340 16,122 ± 5,307
After 72 hours 24,903 ± 13,093 18,951 ± 7,113
HES (ml)
After 24 hours 1 patient: 200 3,431 ± 1,674
After 48 hours 2 patients: 200 each 4,966 ± 2,461
After 72 hours 4 patients: 1,325 ± 538 6,094 ± 3,359
Albumin (ml)
After 24 hours 9 patients: 136 ± 70 0
After 48 hours 13 patients: 438 ± 119 0
After 72 hours 11 patients: 627 ± 205 1 patient: 200
* Values are means ± standard deviation unless stated differently. HES, hydroxyethyl starch.
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Outcome Baxter group
(n = 14)
HES group
(n = 16)
Adjusted hazard ratio or mean difference
(95% CI, P value)#
Mortality Overall mortality (%) 2 (14.3) 7 (43.8) Hazard ratio: 7.12 (0.45-112.7, P = 0.16)
Renal parameters Continuous renal replacement 
therapy (%)
1 (7.1) 4 (25.0) Hazard ratio: 6.16 (0.07-505.7, P = 0.42)
Creatinine clearance 24 hours 125.9 (20.1) 102.5 (38.8) Mean difference: -6.5 (-26.8 to 13.7, P = 0.51)
48 hours 125.9 (25.6) 95.6 (40.3) Mean difference: -14.7 (-37.8 to 8.4, P = 0.20
72 hours 124.2 (33.4) 97.4 (47.2) Mean difference: -4.8 (-28.3 to 18.6, P = 0.67)
Urinary output 72 hours 165.1 (53.1) 135.8 (59.3) Mean difference: -9.7 (-56.6 to 37.2, P = 0.67)
Pulmonary parameters ARDS (%) 4 (28.6) 3 (18.8) Hazard ratio: 1.26 (0.14-11.35, P = 0.84)
Ventilator days 7.4 (11.0) 12.3 (19.7) Mean difference: -2.4 (-12.9 to 8.2, P = 0.65)
Horowitz 72 hours 237.2 (98.3) 225.4 (85.7) Mean difference: 17.5 (-51.7 to 86.6, P = 0.61)
Surgical parameters Beginning of surgical treatment
within first 3 days (%)
10 (71.4) 9 (56.3) Hazard ratio: 2.00 (0.58-6.93, P = 0.27)
Time to complete surgical 
coverage (days)
23.0 (15.7) 31.9 (30.8) Mean difference: 1.7 (-25.2 to 28.6, P = 0.89)
Other parameters Sepsis (%) 5 (35.7) 6 (37.5) Hazard ratio: 0.95 (0.16-5.56, P = 0.95)
Hospital days 32.4 (16.1) 28.6 (20.7) Mean difference: -6.7 (-22.9 to 9.6, P = 0.40)
ICU days 27.0 (14.1) 23.6 (17.4) Mean difference: -7.6 (-21.1 to 5.8, P = 0.25)
# Multivariable logistic regression analysis or linear regression analysis with outcome as independent and groups as dependent variable with 
adjustment for age, gender percent burn, acute physiology and chronic health evaluation (APACHE) II, baseline creatinine. ARDS, adult 
respiratory distress syndrome; CI, confidence interval; HES, hydroxyethyl starch.
A potential explanation for the large effect of possibly
increased mortality in the HES 200/0.5 (10%) group
might be the detected six-fold higher rate of renal failure
needing CRRT. There is strong evidence for increased
mortality after renal failure in ICU patients [24]. In a
large multicenter trial an overall mortality of 60.3% in
ICU patients with acute renal failure was found [25].
About 33 to 66% of administered hyperoncotic HES is
excreted in the urine in the first 24 hours after infusion
[26]. Some hyperoncotic HES remains in circulation for a
long time and a substantial proportion accumulates in var-
ious tissues, including the kidneys. In dogs, hyperoncotic
HES deposition was demonstrated by histopathology in
intravascular and interstitial spaces, parenchymal liver
cells, proximal renal tubular cells, and phagocytes in liver,
spleen, lymph nodes and other organs [27]. There are
many case studies describing acute deterioration of pre-
existing renal impairment after the administration of
hyperoncotic HES [28,29]. Interestingly, in the HES group
both of the two patients with the highest baseline creati-
nine level (> 110 mmol/l) died. Renal biopsies of such
patients often show osmotic nephrosis-like lesions [30].
There are outcome studies after hyperoncotic HES
administration, but none deal with severely burned
patients. In a multicenter randomized trial of 129 patients
with severe sepsis or septic shock, hyperoncotic HES
administration was an independent risk factor for acute
renal failure, with an adjusted odds ratio of 2.5 [31]. Renal
failure after hyperoncotic HES hemodilution was also
described in patients after cardiac surgery [32,33],
abdominal surgery [34], and renal transplantation [35].
Our results are clearly in line with the VISEP trial. A
hyperoncotic 10% HES 200/0.5 was administered in both
studies, and the manufacturers maximal amount of 20
ml/kg/24 hours of HES was also exceeded in 11 of 16
(68%) of our patients. Thus, we must emphasize that the
overtreatment with 'old' hyperoncotic HES 200/0.5 (10%)
may at least in part have been responsible for the possible
negative effects of HES on morbidity and mortality in our
study population.
Furthermore, we could not discriminate a reduction of
ARDS. In another studies the infusion of additional albu-
min in severe burns was able to reduce the total amount
of fluids during resuscitation. Interestingly, extravascular
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after such treatment [36]. In one study comparing col-
loids with crystalloids more saline than colloid solutions
was infused, cardiac output increased more in the colloid
groups, and HES seemed to ameliorate increased pulmo-
nary permeability [37]. In contrast, our data could not
demonstrate that the administration of HES 200/0.5
(10%) could improve pulmonary function.
The incidence of sepsis in ICU patients is well docu-
mented and analyzed. It affects about 40% of ICU admis-
sions, severe sepsis occurs in about 30%, and septic shock
in 15% [38]. The incidence of sepsis in our study did not
differ between the groups. About one-third in each group
developed sepsis, which is in line with the literature. Also,
we could not find any significant differences in inflamma-
tion markers (WBC, CRP), as well as in length of hospital
stay and ICU days.
In a rabbit model, intraoperative profound hemodilu-
tion with hyperoncotic HES did not interfere with small-
intestinal wound healing as long as postoperative haemo-
Figure 1 Kaplan-Meier survival curve and causes of death. Large effect towards a seven-fold higher mortality in the HES group (adjusted hazard 
ratio 7.12; P = 0.16). ARDS, acute respiratory distress syndrome; HES, hydroxyethyl starch.
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Another study showed that the infusion of hyperoncotic
HES and saline reduced acute microvascular deteriora-
tions, trauma-induced inflammatory response and tissue
edema in rats [40]. In our study, there was no difference
regarding either the beginning of the surgical procedures
within the first three days after trauma or with respect to
the time to complete coverage of the burned body surface
areas. Therefore, we cannot support the concerns about
impaired wound healing after the application of colloids.
Study limitations
This study was not a randomized controlled trial with
blinding of patients and physicians. Although we adjusted
for potential confounders there might be residual con-
founding in our estimates. Also, the sample size was small
leading to imprecise estimates. For example, although we
observed a higher mortality rate in patients with HES, the
difference was not significant. Nevertheless, the detec-
tion of a seven-fold higher mortality in this prospective
interventional study with such a small sample size is an
impressive finding and has to be interpreted very care-
fully. A similar statistical situation was the CLARICOR
(effect of clarithromycin on mortality and morbidity in
patients with ischemic heart disease) study, in which the
analysis of clarithromycin in patients with stable coro-
nary heart disease showed also a non-significant hazard
ratio [41], but the Food and Drug Administration reacted
on that study with a warning notice. In our study the non-
significance might be a consequence of the small sample
size. Hence, in a 'dark' field without data from random-
ized controlled trials and with regard to the ongoing
debate after the VISEP study these results are important,
especially as no randomized controlled trial data are
available.
There was some protocol violation as four patients of
the Baxter group received HES during operating proce-
dures, but not during the first 24 hours after trauma. The
amount of HES was relatively small compared with the
whole administered fluids. This fact theoretically would
have reduced the difference between the groups, because
HES could have deteriorated the patients in the Baxter
group.
As mentioned above there was a trend to a difference in
age between the groups, which was statistically appropri-
ately adjusted. Therefore, a hazard ratio of 7.12 is a mas-
sive difference in mortality and hardly explainable by the
difference of baseline characteristics only. However, if a
randomized controlled trial was designed based on the
mortality rates we observed (44% in the HES group and
14% in the Baxter group) and to detect a significant dif-
ference at a significance level of 0.05 and a power of 80%,
it would require 42 patients per group (without drop-
outs).
Figure 2 Bloodmarkers at days one, two, three and seven. (a) He-
matocrit, (b) white blood count, (c) C-reactive protein, (d) glutamat-
pyruvat-transaminase (GPT) and (e) glutamat-oxalacetat-transaminase 
(GOT). Baxter group black bars, hydroxyethyl starch (HES) group grey 
bars. Plots show mean ± standard deviation, analysis of variance for re-
peated measurements. There were no differences between the 
groups.
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In summary, our study showed that the application of
hyperoncotic HES 200/0.5 (10%) within the first 24 hours
after severe burn injury may be associated with increased
mortality and renal failure as compared with traditional
fluid resuscitation with crystalloids only, but findings
were not significant.
Key messages
• There is some indication that HES 200/0.5 (10%) 
may be associated with increased mortality and renal 
failure in patients with severe burn injury, but find-
ings are not significant.
• HES 200/0.5 (10%) should be used with caution in 
patients with severe burn injury.
• Successful surgery in burn injury is not affected by 
the application of HES 200/0.5 (10%).
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